<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126056">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883674</url>
  </required_header>
  <id_info>
    <org_study_id>PLC-021742</org_study_id>
    <nct_id>NCT01883674</nct_id>
  </id_info>
  <brief_title>Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.</brief_title>
  <acronym>PRO</acronym>
  <official_title>Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairy Farmers of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project evaluates the use of different types of proteins from various food sources
      after an exercise session, on muscle mass and physical capacity in aged sarcopenic men (who
      have low muscle mass). Specifically, researchers want to:

        -  Examine the efficiency of protein intake after exercise on muscle mass and physical
           abilities;

        -  Examine the impact of exercise and proteins on blood lipids (LDL cholesterol, HDL
           cholesterol, total cholesterol and triglycerides);

        -  Examine the impact of exercise and proteins on liver enzymes;

        -  Examine the impact of exercise and proteins on a hormone that controls hunger;

        -  Evaluate the program's impact on the ability of the body to produce energy.

      All participants are exercising (resistance training) and ingest one of the 3 different
      sources of proteins, immediately after training:

        -  Milk proteins (from milk beverage)

        -  Essential amino acids (added to a soya beverage)

        -  No protein (rice beverage - control group)

      Our hypothesis is that proteins from milk will induce a gain in muscle mass and physical
      function equivalent to the essential amino acids (EAA). We anticipate that both milk
      proteins and EAA will be both superior to control group.

      This would represent an interesting finding since milk is more accessible, palatable and
      cheaper than essential amino acids commercial mix.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Muscle mass</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative strength</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood markers of inflammation</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasmatic IL-6 anf TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lipid profile</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apolipoproteins (Apo-AI, Apo-AII, Apo-B); Total cholesterol, HDL, LDL and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma creatinine</measure>
    <time_frame>At baseline, mid (8th week) and post intervention (17th week)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood marker on renal function will be assessed to ensure the safety of the supplementation of protein intake on renal function in sarcopenic men.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood markers of fatty liver</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyltransferase (GGT) and Alkaline phosphatase (ALP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extracellular HSP72</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Dietary intakes</measure>
    <time_frame>At baseline, mid (8th week) and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
    <description>3-day food record - Control variable (in order to verify if changes we observe through the intervention are accountable or not for dietary intakes)</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity level</measure>
    <time_frame>At baseline and post intervention (17th week)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physical Activity Scale for the Elderly (PASE) - Control variable (in order to verify if changes we observe through the intervention are accountable or not for daily physical activity level)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Milk proteins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will do a resistance training + milk proteins (milk beverage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essential amino acids (add to soya bvg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will do a resistance training + essential amino acids (added to soya beverage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No protein (control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resistance training</intervention_name>
    <description>All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.</description>
    <arm_group_label>Milk proteins</arm_group_label>
    <arm_group_label>Essential amino acids (add to soya bvg)</arm_group_label>
    <arm_group_label>No protein (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65-75 years

          -  francophone or understanding French

          -  muscle mass index &lt; 10.75 kg/m2 (Janssen et al, 2004)

          -  body mass index &lt;30kg/m²

          -  weight stable (&lt; 2 kg) for 6 mo

          -  no resistance exercise for 3 years

          -  controlled blood pressure for at least 6 months

        Exclusion Criteria:

          -  major physical disability

          -  medical treatment influencing metabolism

          -  statin treatment

          -  diagnosis or any sign of kidney disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle J. Dionne, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Maltais, M.Sc.</last_name>
    <phone>1-819-780-2220</phone>
    <phone_ext>45310</phone_ext>
    <email>mathieu.maltais@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine Perreault, B.Sc.</last_name>
    <phone>1-819-780-2220</phone>
    <phone_ext>45274</phone_ext>
    <email>karine.perreault@usherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de recherche sur le vieillissement</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Fisch, nurse</last_name>
      <phone>1-819-780-2220</phone>
      <phone_ext>45141</phone_ext>
      <email>martine.fisch@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Isabelle J. Dionne, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcopenia</keyword>
  <keyword>Physical capacity</keyword>
  <keyword>Muscle force</keyword>
  <keyword>Muscle quality</keyword>
  <keyword>Milk proteins</keyword>
  <keyword>Essential amino acids</keyword>
  <keyword>Proteins</keyword>
  <keyword>Resistance training</keyword>
  <keyword>Exercice</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
